Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.47 |
| ▸ | RAB9A | P51151 | 6/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1973580 | 1.00 | MEN1 (0.53) | MEN1KMT2ACTDSP1SMN1; SMN2RAB9A | |
| SCHEMBL2617527 | 1.00 | MEN1 (0.53) | MEN1KMT2ACTDSP1SMN1; SMN2RAB9A | |
| SCHEMBL13925576 | 0.91 | MIF (0.49) | MEN1KMT2ACTDSP1SMN1; SMN2RAB9A | |
| SCHEMBL4304419 | 0.86 | MIF (0.45) | MEN1KMT2ASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL11928961 | 0.86 | MIF (0.45) | MEN1KMT2ASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL4305863 | 0.86 | MIF (0.45) | MEN1KMT2ASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL13499996 | 0.85 | PLA2G7 (0.40) | MEN1KMT2ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL3384931 | 0.84 | LMNA (0.52) | MEN1KMT2ASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL6118220 | 0.84 | LMNA (0.52) | MEN1KMT2ASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL687935 | 0.84 | LMNA (0.52) | MEN1KMT2ASMN1; SMN2RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11667631-B2 | FGFR4 inhibitor, preparation method therefor, and applications thereof | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-06-06 | — | — | US | disclosed |
| US-20190276451-A1 | FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2019-09-12 | — | — | US | disclosed |
| EP-3444250-A1 | FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) | 2019-02-20 | — | — | EP | disclosed |
| EP-3124469-A1 | PROCESS FOR PRODUCING 1-ARYLIMINO-2-VINYLCYCLOPROPANECARBOXYLIC ACID DERIVATIVE | Kaneka Corporation (JP) | 2017-02-01 | — | — | EP | disclosed |
| US-9259723-B2 | Quaternary ammonium salt | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-02-16 | — | — | US | disclosed |
| US-8742162-B2 | Method for producing optically active 1-amino-2-vinylcyclopropanecarboxylic acid ester | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-06-03 | — | — | US | disclosed |
| US-8637449-B2 | Processes for preparing protease inhibitors of hepatitis C virus | MERCK SHARP & DOHME CORP. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637449-B2 | Processes for preparing protease inhibitors of hepatitis C virus | MERCK SHARP & DOHME CORP. (US) | 2014-01-28 | — | — | US | disclosed |
| EP-2684864-A1 | METHOD OF PRODUCING OPTICALLY ACTIVE 1-AMINO-2-VINYLCYCLOPROPANE CARBOXYLIC ACID ESTER | Sumitomo Chemical Company Limited (JP) | 2014-01-15 | — | — | EP | disclosed |
| US-20130338392-A1 | METHOD OF PRODUCING OPTICALLY ACTIVE 1-AMINO-2-VINYLCYCLOPROPANE CARBOXYLIC ACID ESTER | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-12-19 | — | — | US | disclosed |
| WO-2010042473-A1 | BIARYL SPIROAMINOOXAZOLINE ANALOGUES AS ALPHA2C ADRENERGIC RECEPTOR MODULATORS | SCHERING CORPORATION (US) | 2010-04-15 | — | — | WO | disclosed |
| US-7666907-B2 | Salts of trimebutine and N-desmethyl trimebutine | ANTIBE THERAPEUTICS INC. (CA) | 2010-02-23 | — | — | US | disclosed |
| EP-2024323-A1 | SALTS OF TRIMEBUTINE AND N-DESMETHYL TRIMEBUTINE | Antibe Therapeutics Inc. (US) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007140611-A1 | SALTS OF TRIMEBUTINE AND N-DESMETHYL TRIMEBUTINE | ANTIBE THERAPEUTICS INC. (CA) | 2007-12-13 | — | — | WO | disclosed |
| US-20070275905-A1 | SALTS OF TRIMEBUTINE AND N-DESMETHYL TRIMEBUTINE | ANTIBE THERAPEUTICS INC. (CA) | 2007-11-29 | — | — | US | disclosed |
| EP-0520336-A2 | Aldehyde derivatives and their use as calpain inhibitors | FUJIREBIO Inc. (JP) | 1992-12-30 | — | — | EP | disclosed |
| US-4730006-A | BACTERICIDES | MERRELL DOW PHARMACEUTICALS INC. (US) | 1988-03-08 | — | — | US | disclosed |
| US-4478758-A | CYCLIZATION OF AMINOACETIC ACIDS WITH ALPHA, OMEGA-DISUBSTITUTED ALKANES | BASF AKTIENGESELLSCHAFT (DE) | 1984-10-23 | — | — | US | disclosed |
| EP-0047516-B1 | PROPYLAMINE DERIVATIVE AND PROCESS OF MANUFACTURING THE SAME | TORAY INDUSTRIES, INC. (JP) | 1984-01-04 | — | — | EP | disclosed |
| EP-0047516-A1 | Propylamine derivative and process of manufacturing the same | TORAY INDUSTRIES, INC. (JP) | 1982-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190276451-A1 | FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF | FGFR4, FGFR1, FGFR2 | MEN1 1112/4885KMT2A 2300/4885CTDSP1 2844/4885 |
| US-20130338392-A1 | METHOD OF PRODUCING OPTICALLY ACTIVE 1-AMINO-2-VINYLCYCLOPROPANE CARBOXYLIC ACID ESTER | ALAD, AASDHPPT, TASP1 | MEN1 4231/4885KMT2A 3299/4885CTDSP1 150/4885 |
| US-11667631-B2 | FGFR4 inhibitor, preparation method therefor, and applications thereof | FGFR4, FGFR1, FGFR2 | MEN1 1112/4885KMT2A 2300/4885CTDSP1 2844/4885 |
| US-20070275905-A1 | SALTS OF TRIMEBUTINE AND N-DESMETHYL TRIMEBUTINE | SI, VIP, TRIM59 | MEN1 3352/4885KMT2A 2505/4885CTDSP1 3991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.